PharmEco Group of Companies

Search

RU | EN

BioJet – EN
  • About
    • General information
    • Administration
    • Pharmacovigilance
    • Business ethics
  • Production
  • Our products
  • News
  • Contacts

Vertex invested 190 million rubles in equipping its pharmaceutical complex

Since the beginning of 2025, the pharmaceutical company Vertex has invested more than 194 million rubles into its innovative production complex located in the special economic zone “Saint Petersburg.” The main part of the funds has been allocated to equipping production lines for solid dosage forms, including cardiological and hormonal drugs. The key expenses are related to the supply of new equipment, while a significant share has also gone into R&D and other types of work.

The company continues to equip a new solid dosage production line within one of the complex’s workshops, preparing it for a technology transfer (relocation from another site) and for pilot production runs of a drug used to treat arterial hypertension.

In addition, Vertex is preparing the third production line of its hormonal drug workshop, which will also focus on solid dosage forms. Two other lines — for liquid and soft hormonal medications — were launched in 2024. The total area of the workshop is 1,700 sq. m.

“The company is steadily following its development strategy to ensure the availability of in-demand medicines for the population,” commented Georgy Pobelyansky, CEO of Vertex.

By September 2025, the company’s total investments into the innovative production complex since the start of the project reached nearly 10.76 billion rubles. Vertex became a resident of the Saint Petersburg special economic zone in 2010, began construction in 2013, and by 2020 had gradually commissioned three phases of the facility. The complex covers more than 56,500 sq. m and is located at the “Novo-Orlovskaya” site of the SEZ. The second facility — a production and warehouse building operated by the subsidiary LLC Vertex Co. — is also located there.

Overall, the company’s combined investments in both facilities during the first eight months of 2025 exceeded 290 million rubles, and since the beginning of the projects — 12.95 billion rubles.

The total area of the two Vertex facilities is more than 78,000 sq. m.

Source: Press service of the Ministry of Industry and Trade of Russia, 10.09.2025

Current news

  • January 13, 2026

    The average cost of bringing a medicinal product to market has tripled over 20 years

    Over the past 20 years, the average cost of bringing a medicinal product to market…

  • January 13, 2026

    More than 60% of the Russian pharmaceutical market is occupied by foreign drugmakers

    Despite sanctions and expectations of a complete withdrawal of foreign businesses, international pharmaceutical companies continue…

  • January 13, 2026

    The Ministry of Industry and Trade will align the regulatory framework with the transition to EAEU GMP

    The Ministry of Industry and Trade of Russia has prepared a draft government resolution proposing…

  • January 13, 2026

    WHO Director-General: Pandemic agreement to be opened for signature after May

    WHO member states are negotiating an important annex to the agreement — a pathogen access…

  • January 13, 2026

    The Ministry of Industry and Trade proposes extending transition periods related to confirmation of the country of origin of medicines and a number of medical devices

    Relevant draft amendments to resolutions of the Government of the Russian Federation*, prepared by the…

LLC “BioJet”. all rights reserved

  • Legal information